Filing and reporting period
The supplied filing is Leap Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed May 14, 2020. This does not match the request metadata naming Cypherpunk Technologies Inc.; the summary below reflects the filing text provided.
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate is DKN-01; it deprioritized TRX518 development and suspended enrollment in its trials in November 2019. Neither candidate has FDA approval.
Financial results and liquidity
Amounts below are in U.S. dollars; figures are rounded to millions unless otherwise stated.
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| License revenue | $0.375 million | None |
| Research and development expense | $4.603 million | $6.790 million |
| General and administrative expense | $2.153 million | $2.005 million |
| Operating loss | $6.381 million | $8.795 million |
| Net loss | $7.231 million | $8.603 million |
| Net loss attributable to common stockholders | $17.305 million; $0.55 per share | $8.962 million; $0.47 per share |
| Cash used in operating activities | $3.926 million | $6.868 million |
Net loss attributable to common stockholders includes $9.399 million related to preferred-stock beneficial conversion features, $0.372 million of preferred dividends, and a $0.303 million warrant down-round dividend. These items increased the loss attributable to common stockholders relative to the reported net loss.
Cash and cash equivalents were $25.465 million at March 31, 2020, versus $3.891 million at December 31, 2019. Current assets were $25.984 million and current liabilities $9.199 million. Total liabilities were $10.778 million, including $0.833 million of lease liabilities; the filing reports no conventional borrowings. Stockholders’ equity was $17.964 million, compared with a $1.749 million deficit at year-end. There is no meaningful operating margin to assess given the company’s development-stage profile and limited license revenue.
Financing activities provided $25.605 million in cash, principally from the January private placement. The company reported no investing cash flows. Management said existing cash was expected to fund operating expenses for at least 12 months from issuance of the statements, while warning that losses are expected to continue and that additional financing or collaboration funding may be needed.
Material changes and business developments
- Research and development expense declined $2.187 million year over year, including lower DKN-01 and TRX518 program spending. Management attributed the reduction mainly to clinical-trial timing and lower consulting fees.
- General and administrative expense rose $0.148 million, primarily from payroll and professional fees, partly offset by lower stock-based compensation.
- Foreign currency results shifted to a $0.991 million loss from a $0.042 million gain, reflecting exchange-rate changes associated with the Australian subsidiary.
- On January 3, 2020, Leap entered an exclusive option and license agreement with BeiGene for DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap received $3 million upfront, recognized $0.375 million as Q1 license revenue, and recorded $2.625 million as deferred revenue. Leap may receive up to $132 million in option exercise and milestone payments, plus tiered royalties; these future amounts are contingent.
- A January financing raised approximately $27 million gross through preferred stock. Following shareholder approval in March, Series A converted into pre-funded warrants for 14.414 million shares and Series B into 11.531 million common shares. Investors also received warrants covering an equal number of shares at $2.11. Common shares issued and outstanding rose to 35.799 million at quarter-end.
Outlook, risks, and unusual items
- Leap planned to continue DKN-01 development and expected research and development spending to rise, subject to funding. It described a planned BeiGene-associated study of DKN-01 plus tislelizumab, with first dosing expected in the second half of 2020; this is a stated expectation, not a reported outcome.
- Management described clinical results in selected gynecologic and esophagogastric cancer groups, including response and survival observations associated with DKK1-high tumors or Wnt-activating mutations. These are investigational findings and do not establish efficacy or regulatory approval.
- COVID-19 could disrupt clinical-trial enrollment, laboratory work, sites, vendors, and collaborators, causing delays or increased costs. The extent of the effect was uncertain.
- The company has no approved product, product-sales revenue, profitable operations, or history of positive operating cash flow. It warned that failure to obtain funding, spending above forecasts, or failure to receive Australian R&D incentives could force reductions or delays in research and development and other spending.
- Patent opposition proceedings involving TRX518 remained ongoing before the European Patent Office; one related patent had been revoked by the opposition division and was under appeal. The filing reports no accrued material liability for these matters.
- A roughly $662,000 Paycheck Protection Program note received after quarter-end was repaid in full on April 28, 2020, following the company’s decision to cancel it.
Most important facts for investors to verify
- Confirm issuer identity: the supplied filing is for Leap Therapeutics, Inc., not Cypherpunk Technologies Inc.
- Track cash burn against management’s stated 12-month runway and assess the timing and terms of any additional financing.
- Review the full BeiGene agreement for option deadlines, development obligations, milestone conditions, royalty terms, and termination rights.
- Assess dilution from the pre-funded and coverage warrants, outstanding warrants, options, and restricted stock units; the filing reports substantial potential share issuance.
- Verify subsequent clinical-trial progress and the actual effects of COVID-19 disruptions; the filing’s outlook and clinical observations are uncertain and not guarantees.
- Monitor the TRX518 patent appeals and any resulting effect on the company’s intellectual-property position.